financetom
Business
financetom
/
Business
/
GM co-leads $39 mln funding for EV battery materials startup Addionics
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GM co-leads $39 mln funding for EV battery materials startup Addionics
Jul 25, 2024 4:36 AM

LONDON, July 25 (Reuters) - Israeli battery technology

company Addionics has raised $39 million from investors

including General Motors' ( GM ) venture capital arm to help

commercialise its copper and aluminium electrodes for electric

vehicle batteries, it said on Thursday.

GM Ventures co-leads the B Series funding round with Israeli

tech venture fund Deep Insight. Swedish truck maker Scania,

owned by Volkswagen's Traton also

participated in the investment round.

As well as investing in Addionics, GM and Scania are

potential customers for the company's porous, three-dimensional

copper and aluminium electrode battery materials that use less

material - including 60% less copper.

Addionics says the electrodes, which look like sheer silk

scarves when held up to the light, provide faster charging and

boost EV range by 30%. It forecasts savings for automakers up to

$7.50 per kilowatt hour.

"Addionics' current collector design shows promise in

enabling improved battery performance at a lower cost," GM

Ventures managing director Anirvan Coomer said in a statement.

"We are eager to support the company's growth and look forward

to continuing to explore opportunities to collaborate in the

future."

Earlier this year, Addionics said it plans a $400 million

U.S. factory to make copper anodes for EV batteries starting in

2027 to eventually supply enough for about 1 million EVs a year.

Addionics CEO Moshiel Biton said that in late 2024 the

company will start delivering battery cells to automakers to

test and that it is on track to deliver product at scale by 2027

or 2028.

He said the company has been working with or talking to

virtually all the major automakers in Europe, Japan and the

United States.

"Legacy automakers are losing money building EVs," Biton

said. "Any technology that allows them to reduce cost and

improve performance, that's the holy grail."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Germany's Commerzbank has a bumpy history with big M&A
Germany's Commerzbank has a bumpy history with big M&A
Sep 21, 2024
FRANKFURT (Reuters) -Commerzbank is poised to put CFO Bettina Orlopp in charge of talks with UniCredit when the German bank's supervisory board meets next week, two people with knowledge of the matter said, as the Italian rival considers a takeover. Commerzbank has, like some other banks, had a rocky history with big mergers and acquisitions over the years. These are...
Musk's Neuralink gets FDA's breakthrough device tag for 'Blindsight' implant
Musk's Neuralink gets FDA's breakthrough device tag for 'Blindsight' implant
Sep 21, 2024
(Reuters) -Elon Musk's brain-chip startup Neuralink said on Tuesday its experimental implant aimed at restoring vision received the U.S. Food and Drug Administration's breakthrough device designation. The FDA's breakthrough tag is given to certain medical devices that provide treatment or diagnosis of life-threatening conditions. It is aimed at speeding up development and review of devices currently under development. The experimental...
TIMELINE-Germany's Commerzbank has a bumpy history with big M&A
TIMELINE-Germany's Commerzbank has a bumpy history with big M&A
Sep 21, 2024
(Updates timeline originally published on Sept. 11 with latest developments) By Tom Sims FRANKFURT, Sept 18 (Reuters) - Commerzbank is poised to put CFO Bettina Orlopp in charge of talks with UniCredit when the German bank's supervisory board meets next week, two people with knowledge of the matter said, as the Italian rival considers a takeover. Commerzbank has, like some...
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Sep 21, 2024
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children. Recent published studies report up to 10.1 million U.S. children (ages 6-17) are estimated to suffer from pediatric OSA. Vivos’ DNA appliance is non-invasive, safe, comfortable, affordable, and highly effective....
Copyright 2023-2026 - www.financetom.com All Rights Reserved